Theravance Biopharma (TBPH) Non-Current Deffered Revenue (2013 - 2023)

Theravance Biopharma (TBPH) has 11 years of Non-Current Deffered Revenue data on file, last reported at $175000.0 in Q3 2023.

• On a quarterly basis, Non-Current Deffered Revenue fell 12.06% year-over-year to $175000.0 in Q3 2023; TTM through Sep 2023 was $175000.0, a 12.06% decrease from a year earlier, with the FY2022 full-year figure at $192000.0, down 38.06% from the prior year.
• Non-Current Deffered Revenue for Q3 2023 stood at $175000.0, down from $181000.0 in the prior quarter.
• Over the last five years, Non-Current Deffered Revenue for TBPH reached as high as $21.7 million in Q1 2019 and fell as low as $175000.0 in Q3 2023.
• Historically, Non-Current Deffered Revenue has averaged $3.7 million across 5 years, with a median of $329000.0 in 2021.
• Across the five-year window, Non-Current Deffered Revenue soared 101.32% in 2019 and sank 96.02% in 2021, its largest moves.
• Year by year, Non-Current Deffered Revenue stood at $6.8 million in 2019, then sank by 94.85% to $348000.0 in 2020, then retreated by 10.92% to $310000.0 in 2021, then slumped by 38.06% to $192000.0 in 2022, then fell by 8.85% to $175000.0 in 2023.
• Per Business Quant data, the three most recent Non-Current Deffered Revenue figures were $175000.0 in Q3 2023, $181000.0 in Q2 2023, and $187000.0 in Q1 2023.